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961Transcatheter Valve Implantation in
Failed Surgically Inserted Bioprosthesis
Review and Practical Guide to Echocardiographic Imaging
in Valve-in-Valve ProceduresABSTRACTha
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MaAn increased use of bioprosthetic heart valves has stimulated an interest in possible transcatheter options for bio-
prosthetic valve failure given the high operative risk. The encouraging results of transcatheter aortic valve implantation in
high-risk surgical candidates with native disease have led to the development of the transcatheter valve-in-valve (VIV)
procedures for failed bioprostheses. VIV procedures are unique in many ways, and there is an increased need for
multimodality imaging in a team-based approach. The echocardiographic approach to VIV procedures has not previously
been described. In this review, we summarize key echocardiographic requirements for optimal patient selection, proce-
dural guidance, and immediate post-procedural assessment for VIV procedures. (J Am Coll Cardiol Img 2015;8:960–79)
© 2015 by the American College of Cardiology Foundation.I mprovements in bioprosthetic surgical heartvalve (SHV) durability and the desire to avoidlong-term anticoagulation has led to an increased
use of bioprosthetic, as opposed to mechanical heart
valves, even in younger patients (1–4). When bio-
prosthetic valves fail, reoperation, particularly if
emergently required, is associated with a 5% to 11%
operative mortality (5–8), increasing to 15% with
concomitant coronary artery disease (9). Numerous
investigators have reported the feasibility of trans-
catheter heart valve (THV) implantation into a failed
SHV (the valve-in-valve [VIV] procedure) (10–14).
A recent report from the VIVID (Valve-in-Valve
International Data) registry included data on 459
patients from 55 participating sites undergoing
aortic VIV with either a balloon-expandable or self-
expanding prosthesis between 2007 and 2013 (13).
The reported 30-day mortality of 7.6% (higher for
stenotic valves than regurgitant valves) suggests
this procedure may be an acceptable alternative
to surgical reoperation for degenerated aortic bio-
prosthetic valves.
Multimodality imaging has proven to be indispens-
able for the transcatheter aortic replacement (TAVR)
procedural guidance (15,16). Both 2-dimensional ands received an honorarium and research grant from Medtronic. Dr. Bapat
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nuscript received January 12, 2015; revised manuscript received January3-dimensional (3D) transesophageal echocardiography
(TEE) have become integral parts of pre-procedural,
intraprocedural, and immediate post-procedural as-
sessment (17). Numerous guidelines, reviews, and
consensus statements have delineated the role of im-
aging for TAVR (15,16,18), but none have speciﬁcally
discussed the utility of TEE imaging for the
VIV procedure. The following review discusses the
role of echocardiography as it relates to patient
screening, procedural guidance, and immediate post-
procedural assessment for the VIV procedure (Central
Illustration).
REVIEW OF SURGICAL BIOPROSTHETIC
VALVE CONSTRUCTION AND
MEASUREMENTS
An understanding of SHV anatomy is essential to
optimize VIV outcomes. Biological valves contain
leaﬂets made from biological materials, including
porcine, bovine, or equine tissue (xenografts), homo-
grafts, or autografts. Bioprosthetic valves are divided
into 2 main types: stentless or stented (19). For the
stented bioprosthesis, there are 3 components: the
stent frame, the biological tissue leaﬂets, and theis a consultant to Edwards Lifesciences, Boston Sci-
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ABBR EV I A T I ON S
AND ACRONYMS
3D = 3-dimensional
EOA = effective oriﬁce area
ID = internal diameter
LV = left ventricular
SHV = surgical heart valve
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiogram
THV = transcatheter heart
valve
VIV = valve-in-valve
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962sewing ring. The leaﬂets of a SHV require
support for the valve to function, and 3 struts
at the commissures create its classic “crown”
appearance.
The primary sizing measurement for the
VIV procedure is the smallest internal
dimension (true internal dimension [ID]) of
the surgical bioprosthesis (20). SHV sizing
is not standardized, and the labelled
dimensions including external diameter and
ID vary depending on the manufacturer
(Figure 1). Christakis et al. (21) showed that
the labeled size for a SHV was 1 to 4 mm larger
than the true ID of the valve, which varies
depending on the type of bioprosthesis andthe arrangements of the leaﬂets within the stent.
Because the true ID is not routinely reported by man-
ufacturers, a free, downloadable “app”was developed
(the VIV aortic app and VIV mitral app, by V.B. and
UBQO, London, United Kingdom), which provides in-
formation on the anatomic and ﬂuoroscopic appear-
ances of available SHVs, their true ID and suitability,
and the recommended sizes of THVs for each pros-
thesis (22). Although not well validated, oversizing the
pre-existing aortic prosthesis ID by a minimum of
10% will ensure secure anchoring of the implant
within the sewing ring and minimize intervalvular
regurgitation (10). More oversizing may be necessary
for the mitral prosthesis, given reports of late migra-
tion (23). However, severe oversizing will result in
distortion of the transcatheter valve leaﬂets, which
may impact hemodynamics as well as durability.
In addition to the SHV true ID, the stent post and
leaﬂet heights, as well as the leaﬂet location (intra-
annular vs. supra-annular), may inﬂuence VIV proce-
dural outcomes (24). Supra-annular valves sit higher in
the aorta, with the tips of the leaﬂets near the level of
the coronary arteries. In addition, although leaﬂets are
typically attached to the internal aspect of the stent
posts, externallymounted leaﬂetsmay pose additional
problems when the stented THV is deployed and the
SHV leaﬂets act as a “covered stent.” This may result in
coronary occlusion for aortic VIV, and left ventricular
(LV) outﬂow obstruction for mitral VIV.
Stentless bioprosthetic valves are currently limited
to the aortic position and were developed to improve
valve hemodynamics (particularly in the setting of a
small annulus) because they allow for a larger effec-
tive oriﬁce area (EOA) (25). Stentless valves include
homografts and bioprostheses made from porcine
aortic valves or fabricated from bovine pericardium.
These valves have limited ﬂuoroscopically identiﬁ-
able structures, making them particularly challenging
for the VIV procedure.In patients with failed surgical mitral valve repair
at extreme risk for reoperation, numerous investi-
gators have reported successful THV implantation
into surgical mitral valve rings (26,27). Again, an
understanding of the type, size, and shape of the
annuloplasty ring is essential in order to achieve a
good valve–in-ring result.
TYPES OF THVs
There are 3 THVs that have been approved for use
in Europe (CE marked) for VIV procedures: the
Edwards SAPIEN XT Valve (second generation balloon
expandable valve) (Edwards Lifesciences, Irvine, Cal-
ifornia), the Medtronic CoreValve (self-expanding
valve) (Medtronic, Minneapolis, Minnesota), and the
St. Jude Portico valve (St. Jude Medical, St. Paul,
Minnesota) (20). In the United States, the second
generation balloon expandable valve, self-expanding
valve, and Melody valve (transcatheter pulmonary
valve) (Medtronic) are used for VIV procedures. The
second generation balloon expandable valve and
transcatheter pulmonary valve may be used in multi-
ple positions, but the other valves are restricted to
the aortic position. All THVs are composed of biological
tissue leaﬂets suspended within a metallic stent, but
have important differences in their design features and
structure that can be recognized on imaging.
GENERAL ROLE OF ECHOCARDIOGRAPHY
IN VIV PROCEDURES
Although THV sizing is determined by the prior SHV
size, in some patients, the surgical records may not be
available, and the valve size and type may not be
known, so accurate sizing by imaging is essential.
Both computed tomography and TEE have been used
to conﬁrm the ID of the SHV (28–30). Conﬁrmation of
aortic (Figure 2) and mitral (Figure 3) prosthetic IDs by
echocardiography is typically performed using 3D
TEE (29–31). User-deﬁned or zoom 3D volumes are
acquired during a single cardiac cycle because mul-
tibeat acquisitions may introduce splice artifacts.
With multiplanar reconstruction, on-axis short-axis
views of the sewing ring are acquired to measure the
sewing ring ID (Figures 2 and 3D). Care is taken to
avoid measurement of acoustic noise by reducing
gain and measuring only the densest border.
Echocardiography is the primary imaging modality
used to assess the cause and severity of bioprosthetic
valve failure as well as the associated chamber
remodeling and function (19). Acoustic shadowing
by the prosthetic material is the primary pitfall of
imaging the aortic prosthesis by either transthoracic
CENTRAL ILLUSTRATION Summary of Echocardiographic Imaging Recommendations for VIV Procedures
Hamid, N.B. et al. J Am Coll Cardiol Img. 2015; 8(8):960–79.
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964or TEE views; however, TEE views of the mitral
prosthesis are far superior to transthoracic views
(Figure 3) (19,32). Large studies of normal mechanical
and bioprosthetic mitral valve hemodynamics show
that mitral EOA by the pressure halftime method vary
signiﬁcantly and fail to correlate with the actual area
of the prosthetic valve (33–35). Consequently, the
calculation of the EOA should be performed using the
continuity equation for either the aortic or mitral
prosthesis (Figure 3B) (19) with the caveat that the
presence of signiﬁcant regurgitation may lead to an
underestimation of EOA. Planimetry of the oriﬁce
area can also be performed from short-axis trans-
thoracic echocardiography images or with the use of
3D TEE imaging (Figure 3C). If isolated stenosis is the
cause of failure, prosthesis–patient mismatch of the
surgical valve (whether aortic or mitral) should be
excluded (36–38) because a VIV procedure may not
improve the EOA in these patients. If regurgitation is
the primary mode of failure, active endocarditis must
be excluded because this is a contraindication to VIV
implantation. In addition, signiﬁcant paravalvular
regurgitation suggestive of dehiscence is a relative
contraindication to the procedure and would warrant
consideration of an open procedure (39–41). Small
paravalvular leaks around the SHV are not an abso-
lute contraindication to the VIV procedure because
transcatheter closure of these defects can be per-
formed (41).Biological SHV Dimensions
icates the inner diameter (ID) of the stent frame, “B” indicates the
ding the sewing ring or “true ID,” “C” indicates the prosthesis height,
outer sewing ring diameter or external diameter. Reprinted, with
lotte D, Lange R, Martucci G, Piazza N. Transcatheter Heart Valve
ing Surgical Bioprostheses: Technical Considerations and Evidence
rocedures. Heart 2013;99:960–967. SHV ¼ surgical heart valve.Following the VIV implantation, intraprocedural
echocardiography is used to assess procedural re-
sults: transcatheter valve position and stability,
leaﬂet excursion, gradients, and valve area (Figure 4).
Complications of the procedure should always be
excluded: the presence and severity of intravalvular
and intervalvular regurgitation, change in ventricular
size and function, and change in pericardial effusion.
Small intervalvular jets between the SHV and THV
(Figure 4E) are not uncommon and may resolve over
time. Patients with more than mild intervalvular
regurgitation should be considered for a second
balloon dilation. Location-speciﬁc concerns must be
carefully evaluated: coronary obstruction for aortic
VIV and LV outﬂow tract obstruction for mitral VIV.
The incidence of various complications for the VIV
procedure differs, however, from native valve TAVR
(Table 1).
Transthoracic echocardiography is used for long-
term follow-up of the VIV procedure. The initial
transthoracic echocardiogram should be obtained
within 1 month following the implant and then at
regular intervals thereafter. Any increase in gradient
should alert the physician to the possibility of VIV
thrombosis (42,43), and further testing may be
warranted.
INTRAPROCEDURAL IMAGING CONSIDERATIONS
SPECIFIC TO SHV POSITION
The following sections discuss procedural and imag-
ing considerations speciﬁc to the location of the failed
bioprosthesis.
AORTIC BIOPROSTHETIC VIV. Coronary obstruction
has been reported in 2% of VIV procedures but is
signiﬁcantly more common in patients with stenotic
prostheses (3.9%) (13). Coronary obstruction may be
related to the relative location of the artery to the
surgical stent posts as well as the bioprosthetic leaf-
lets. There is a higher risk of obstruction with supra-
annular valves, low-lying coronary arteries, narrow
sinuses, and sinotubular junction, bulky prosthetic
leaﬂets, and lack of a stent frame (i.e., homograft or
stentless valve). Because stentless valves are at
higher risk for coronary obstruction, selected patients
may have a guidewire pre-emptively placed in the
left main coronary artery with a slow, controlled
deployment allowing for underdeployment of the
THV if needed (44). Multiple investigators have also
reported a higher risk of coronary obstruction
with internally stented valves where the leaﬂets are
sewn outside the stent frame (i.e., Mitroﬂow [Sorin
Group Inc., Vancouver, Canada] or Trifecta [St. Jude
Medical, St. Paul, Minnesota] valves) (45,46).
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965Risk for coronary obstruction for native aortic
valve TAVR (47) are similar for the VIV procedure.
TEE can be used to measure the coronary height
above the sewing ring, length of the adjacent
bioprosthetic leaﬂet, severity of calciﬁcation, and
size of the aortic root (sinuses of Valsalva and sino-
tubular junction) (Figure 5, Online Video 1). Balloon
valvuloplasty may be used to observe the patency of
the coronary ostium as well as locate the annulus in
the setting of absent radio-opaque markers; simul-
taneous echocardiographic and ﬂuoroscopic imaging
should be used during this diagnostic procedure
(Figure 6, Online Videos 2 and 3) (10). Intraprocedural
TEE is particularly useful during the VIV procedure to
assess the presence of new wall-motion abnormal-
ities suggestive of hemodynamically signiﬁcant
coronary occlusion and to exclude other etiologiesFIGURE 2 3D TEE for Measurement of True ID
Using multiplanar reconstruction, the on-axis short-axis (green box) or
diameter (ID) of the sewing ring (yellow double arrow). Often the coro
(asterisk) may prevent accurate measurements in this plane. In this inst
dimensional; TEE ¼ transesophageal echocardiography.of hypotension, such as tamponade and severe
regurgitation.
Positioning of the THV will depend on the type of
surgical valve and its implantation location (annular
or supra-annular), as well as the landing zone char-
acteristics (i.e., sewing ring appearance, aortic root
size/height, sinotubular junction, and coronary ostia
location). Bapat et al. (48) have demonstrated that
the narrowest portion of the SHV is at the level of
the sewing ring. In many cases, this can be identiﬁed
ﬂuoroscopically and used as a reference point during
the VIV procedure. However, this is not feasible
when the sewing ring is radiolucent, and in these
cases, echocardiographic imaging may prove partic-
ularly useful (49). Malpositioning of the THV in-
creases the risk of complications (50). High
implantation of either the second generation balloonlong-axis (red box) views can be used to measure the true inner
nal plane (blue box) is of limited resolution, and acoustic shadowing
ance, a 21-mm Epic has a true ID of approximately 17 mm. 3D ¼ 3-
FIGURE 3 Baseline Assessment of Mitral Prosthetic Function
Pre-procedural TEE should identify the etiology of biological SHV failure, in this case, stenosis (A) with high intravalvular gradients on Doppler and a calculated
mitral valve area by continuity equation of 0.9 cm2 (B). Planimetry of the prosthetic valve area may be possible with 3D imaging (C). Multiplanar reconstruction (D) of the
3D image is used to measure the internal diameter (double yellow arrows) of the prosthesis. Of note, the dimension in the antero-posterior direction (D1) is smaller than
the dimension in the septo-lateral diriection (D2). LA ¼ left atrium; other abbreviations as in Figures 1 and 2.
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966expandable valve or self-expanding valve risks THV
embolization or coronary obstruction. Low implan-
tation of the second generation balloon expandable
valve can result in aortic regurgitation or prosthetic
leaﬂet overhang that affects valve hemodynamics.
The latter complication may be a risk only in taller
SHVs (i.e., Mitroﬂow and Trifecta) and less likely
with the longer SAPIEN 3 (third generation balloonexpandable valve) transcatheter valve. Low implan-
tation of the self-expanding valve may result in
mitral leaﬂet impingement or loss of the supra-
annular position (and thus maximum opening) of
the THV leaﬂets.
Recent data from the VIVID registry suggests that
high transcatheter device implantation during aortic
VIV procedures is important in order to decrease
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967post-procedural gradients. Optimal hemodynamics
are achieved when self-expanding valve or second
generation self-expanding transcatheter aortic valve
are implanted up to 5 mm below the surgical valve
ring and up to 10% of second generation balloon
expandable valve length. High implantation is espe-
cially advantageous in procedures performed inside
small surgical valves (label size 21 mm and below). It is
important to remember that the landmarks on ﬂuo-
roscopy are not the same as the landmarks on TEE; the
ﬂuoroscopic stent frame is not imaged on echocardi-
ography, but rather the sewing ring itself. This makesFIGURE 4 Imaging Following Mitral VIV
Assessment of the mitral valve-in-valve (VIV) (A) should include an asses
(yellow arrows), and position of the THV (blue arrows) 2 to 3 mm atria
gradients by continuous-wave Doppler (B) with calculation of valve are
multiplanar reconstruction (C) or 3D color Doppler (D). In addition, the s
color jets). THV ¼ transcatheter heart valve.positioning by echocardiography less dependent on
the speciﬁc SHV type and more focused on imaging
the lowest (i.e., sewing ring) and highest (i.e., open
bioprosthetic leaﬂets) extents of the SHV. For the
balloon-expandable THV, positioning is relatively
straightforward. Despite varying crimped lengths,
all second generation balloon expandable valves
shorten approximately 3 mm and primarily from the
ventricular side (51). If the goal is a ﬁnal ventricular
end positioned approximately 1 to 2 mm below the
SHV sewing ring and at most 10% of the second
generation balloon expandable valve length forsment of normal leaﬂet motion with laminar transmitral ﬂow, ﬂared or conical shape of the THV
l to the sewing ring (red arrows). Valve function is assessed by measuring peak and mean
a by either the continuity equation or direct planimetry of the valve using 3-dimensional (3D)
everity of intervalvular mitral regurgitation on 3D color Doppler can easily be assessed (E, red
TABLE 1 Adverse Events Reported With Aortic VIV Procedures
Risk Proﬁle Adverse Event
Lower risk than in native TAVR Signiﬁcant perivalvular leak
Tamponade
Annular rupture
Aortic dissection
Conduction defect
Higher risk than in native TAVR Device malposition
Ostial coronary occlusion
Elevated post-procedural gradients
Adapted from Dvir et al. (24).
TAVR ¼ transcatheter aortic valve replacement; VIV ¼ valve-in-valve.
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968optimal hemodynamics, then the position on echo-
cardiography during pacing should be approxi-
mately 4 to 5 mm below the ventricular edge of the
SHV sewing ring (Figure 7, Online Video 4).FIGURE 5 3D TEE Multiplanar Reconstruction Used for Measuremen
Using multiplanar reconstruction, the long-axis views (red and blue boxes
where the left coronary oriﬁce can be located. The height of the left corona
(in this example, theblue box). This patient had aﬂail left coronary cusp (gre
ostium (red arrow). See Online Video 1. CC ¼ prosthetic coronary cusp; LmPositioning the third generation balloon expand-
able valve with echocardiography focuses instead on
the aortic end of the THV for 2 reasons: 1) shortening
of the third generation balloon expandable valve oc-
curs from the ventricular side; and 2) the third gen-
eration balloon expandable valve height is taller than
any corresponding SHV height. Thus, when the third
generation balloon expandable valve is positioned on
ﬂuoroscopy, TEE imaging should focus on the aortic
end of the THV, ensuring that the original prosthetic
valve leaﬂets are covered while remaining below
the sinotubular junction of the aorta. Because the
deployed third generation balloon expandable valve
is longer than the SHV, the ventricular end of the THV
will extend below the sewing ring of the original
prosthesis, ensuring adequate anchoring of the valve.
Once the pacing position is conﬁrmed on both TEEt of Coronary Arteries
) are aligned to result in an on-axis short-axis view in the green plane,
ry oriﬁce to the annulus is measured in the corresponding long-axis view
en arrow), which in systole extendedwell beyond the left main coronary
ain ¼ left main coronary artery; other abbreviations as in Figure 2.
FIGURE 6 Diagnostic Balloon Valvuloplasty
In this case of a valve-in-valve (VIV) procedure for a stentless valve, a diagnostic balloon valvuloplasty may be used to locate the annulus (red arrows) and assess the risk
of left coronary occlusion (yellow arrow). Both ﬂuoroscopy (A, Online Video 2) and simultaneous multiplane echocardiography (B, Online Video 3) should be used
to image the relevant anatomy. In panel B, the light blue circle in the short-axis view is the outline of the balloon, whereas the orange squiggle represents the displaced
calciﬁed left coronary cusp, which does not obstruct the coronary oriﬁce.
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969and ﬂuoroscopy, the balloon expandable valve is
deployed with slow balloon inﬂation (Online Video 5).
If signiﬁcant acoustic shadowing prevents accurate
positioning from mid-esophageal views, deep gastric
view can be used (Figure 8).FIGURE 7 Positioning of the Transcatheter Valve by Echocardiograp
A (Online Video 4) shows the position of the Sapien (ﬁrst generation ballo
the THV should cover the bioprosthetic valve leaﬂets. The ventricular edg
ring (blue arrow), which corresponds to 15% to 20% below the sewing
valve is not clearly visualized on 2-dimensional imaging, 3D imaging (B)
balloon-expandable valve. Abbreviations as in Figures 2 and 4.Positioning and deployment of the self-expanding
valve does not require pacing. Caution should be
exercised when comparing ﬂuoroscopic and echo-
cardiographic information for positioning this valve
because the long-axis view on echocardiography doeshy
on expandable) valve (yellow arrows) with pacing. The aortic edge of
e of the THV is 4 to 5 mm below the lowest visible edge of the sewing
ring marker ﬂuoroscopically (Online Video 4). If the position of the
can be used. See Online Video 5 for ﬂuoroscopic deployment of the
FIGURE 8 Positioning From the Deep Transgastric View
Simultaneous multiplane imaging from deep transgastric views shows the ventricular edge of the sewing ring (red arrows). The ﬁrst generation
balloon expandable transcatheter heart valve (THV) is not seen in the primary view (A), only in the orthogonal view (B). The ventricular aspect
of the THV is approximately 5 to 6 mm below the imaged sewing ring (yellow arrows). LV ¼ left ventricle.
FIGURE 9 Positioning of the Self-Expanding Valve
The ideal position of the self-expanding valve (yellow arrow) is
at most 4 to 6 mm below the lowest edge of the sewing ring
(blue arrow).
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970not correspond to the coplanar view on ﬂuoroscopy.
For positioning of the self-expanding valve, the
lowest edge of the THV (posterior typically) should be
at most 5 mm below the lowest edge of the imaged
sewing ring. This will ensure the lowest edges of the
THV skirt covers the lowest edge of the prosthetic
sewing ring and that the functioning THV valve
remains supra-annular (Figure 9).
Stentless valves or the Mosaic valve (Medtronic)
lack radio-opaque markers on the sewing ring. In
addition, the mode of failure is more likely regur-
gitation and may not involve signiﬁcant calciﬁcation
of the leaﬂets, making ﬂuoroscopic positioning par-
ticularly challenging (52). Figure 10 (Online Video 6)
is an example of a VIV procedure for a homograft, in
which the sewing ring cannot be accurately identi-
ﬁed by ﬂuoroscopy, and positioning is guided by
intraprocedural TEE using the positioning recom-
mendations outlined in the preceding text.
One suboptimal outcome that occurs more
frequently with VIV is elevated post-procedural gra-
dients. Following the VIV procedure, the expected
valve areas will be lower than for the original surgical
valve given the common under expansion of the
THV and the presence of a stent within the sewing
ring. Mean transaortic gradients reported in the
VIVID registry were 15.9  8.6 mm Hg, with more
than 26.8% of patients having mean gradients of
$20 mm Hg (13). In vitro evaluation of second gener-
ation balloon expandable valve performance revealedVIV mean gradients of 9.1  4.1 mm Hg in a 23-mm
surgical bioprosthesis, 19.5  5 mm Hg in a 21-mm,
and 46.5  9.3 mm Hg in a 19-mm surgical valve (53).
Performing a VIV procedure in a 19-mm surgical
valve is thus discouraged. If a small SHV requires a
VIV procedure, then theoretically, a supra-annular
THV device such as the self-expanding valve,
FIGURE 10 VIV With a Homograft
Because homografts and other stentless valves have no ﬂuoroscopic markers, intraprocedural TEE is particular important to identify the inﬂow
suture line or annulus for positioning of the THV. Panel A shows a color compare mid-esophageal view of an aortic homograft and severe aortic
insufﬁciency. Panel B shows the ﬁrst generation balloon expandable THV following echocardiographic-guided VIV implantation (Online Video 6).
Abbreviations as in Figures 2 and 4.
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971instead of an intra-annular device such as the
second generation balloon expandable valve, might
yield larger valve areas. In the examples in Figure 11A,
the expected mean gradient of 9 mm Hg is seen
with implantation of a #23 second generation bal-
loon expandable valve in a stenotic #23 biopro-
sthesis (Mosaic, Medtronic, Minneapolis, Minnesota).
Figure 11B shows the continuous-wave Doppler
following implantation of a #23 ﬁrst generationFIGURE 11 Continuous-Wave Doppler After VIV
A shows the continuous-wave Doppler following an aortic valve-in-va
bioprosthesis (Mosaic) (A) with calculated effective oriﬁce area (EOA)
self-expanding valve for a stenotic 19-mm bioprosthesis (Epic) with tself-expanding valve for a stenotic #19 bioprosthesis
(Epic, St. Jude Medical, St. Paul, Minnesota); note that
the mean gradient of 21 mm Hg is much lower than the
predicted in vitro gradient with a second generation
balloon expandable valve.
MITRAL BIOPROSTHETIC VIV. LV outﬂow tract
obstruction following mitral VIV procedure is a spe-
ciﬁc complication of this procedure (Figure 12, Online
Video 7). Because the bioprosthetic leaﬂets form thelve (VIV) with a #23 second generation balloon expandable valve for a stenotic 23-mm
of 1.5 cm2. B shows the continuous-wave Doppler following an aortic VIV with a #23
he calculated EOA of 1.1 cm2.
FIGURE 12 LVOT Obstruction
In this post-mitral VIV procedure, the leaﬂets of the bioprosthesis act like a covered stent, with the proximity to the septum (A, yellow arrow) resulting in
markedly turbulent ﬂow in the left ventricular outﬂow tract (B, red arrow, Online Video 7). Continuous-wave Doppler across the LVOT (C) reveals severely elevated
gradients. LVOT ¼ left ventricular outﬂow tract; VIV ¼ valve-in-valve.
FIGURE 13 Biopro
In this 3D dual imag
directly in front of th
obstruction (Online V
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972equivalent of a “covered stent” once a THV is deployed
in the prosthesis, the relationship of the SHV to the LV
outﬂow tract is of signiﬁcant concern. The risk of
outﬂow obstruction includes locating the position of
the stented valve struts (Figure 13, Online Video 8).
Similar to the calculation of LV outﬂow tract clearance
for pre-procedural implantation of a transcatheter
mitral valve replacement (54), a 3D prediction of LVsthetic Strut Position
e of the mitral prosthesis, the anterior valve strut (yellow arrow) is
e left ventricular outﬂow tract (red arrow), which may lead to outﬂow
ideo 8). Abbreviations as in Figures 2, 3, and 8.outﬂow tract obstruction can be made, using the
mitral–aortic angle as well as the size of the basal
septal wall. Using multiplanar reconstruction, the 3D
LV outﬂow tract area following mitral VIV procedure
can be estimated, allowing a prediction of signiﬁcant
obstruction before the procedure (Figure 14).
Access to the mitral bioprosthesis can be achieved
in several ways. The transapical route appears to be
the most suited approach because it provides a
coaxial alignment, hence reducing the risk of malpo-
sition and migration (55–57). The site of puncture/
cannulation can be conﬁrmed with echocardiography
by asking the surgeon to indicate the proposed ven-
tricular cannulation site with extrinsic pressure
from a ﬁnger or probe; using simultaneous biplane
imaging helps ensure accurate positioning (Figure 15A,
Online Video 9). Transgastric views can be used for
localization if acoustic shadowing from the prosthesis
prevents imaging of the apex from mid-esophageal
views (Figure 15B, Online Video 10). Conﬁrming the
cannulation site position is essential to the safety of
the procedure, avoiding right ventricular perforation,
ventricular septal disruption, or papillary muscle
transection (Figure 16, Online Video 11).
Because the second generation balloon expandable
valve shortens typically 3 mm from the atrial side
during deployment, positioning the THV is similar to
aortic VIV with the atrial edge of the valve positioned
approximately 5 mm above (atrial) to the echocardio-
graphically visible sewing ring (Figure 17). Because the
valve shortens during deployment, the base will end
up approximately 2 mm above the sewing ring of the
failed valve. In addition, the ventricular edge of the
FIGURE 14 Estimating Obstruction of the LVOT
Using multiplanar reconstruction, orthogonal views of the prosthesis (yellow arrows indicate the atrial edge of the sewing ring) are aligned to
yield a short-axis view of the mitral valve (MVR). From this view, the 3D LVOT following mitral VIV procedure could be estimated, allowing
a prediction of signiﬁcant obstruction prior to the procedure. Ao ¼ aorta; Ave Diam ¼ average diameter; other abbreviations as in Figures 2, 4,
8, and 12.
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973THV should be imaged, ensuring the LV side of the THV
is positioned far enough into the LV to cover the failed
prosthesis leaﬂets by 1 to 2 mm but avoid LV outﬂow
tract obstruction. Both the ventricular edge and the
atrial edge of the THV should be imaged if possible for
accurate positioning. The VIVID registry reported
intraprocedural device malposition in 5.3% of patients
(58). This may be due to the frequently noncircular
shape of the bioprosthetic sewing ring, noncoaxial
alignment, and a too ventricular-positioned THV. A
recent case report of delayed atrial migration of the
THV following mitral VIV highlights the importance of
oversizing in themitral position and avoiding a parallel
or “nonﬂared” deployment seen with too small a THV
(23). Adequate oversizing (likely >10%) should result
in a “ﬂared” or “conical” deployment, which will pre-
vent atrial migration (Figures 4A and 18).Once the correct valve position is determined, the
valve is deployed under rapid ventricular pacing
(Online Video 12). Post-deployment intraprocedural
echocardiography should be performed to determine
the conical deployment, position and function of the
valve, and assessment of intervalvular regurgitation
(Figure 4, Online Video 13). If the valve is too high in
the atrium (>3 mm), the risk for left atrial emboli-
zation or thrombus formation may be higher. Small
intervalvular regurgitation jets are frequently seen
immediately post-deployment of the THV and may
resolve over time; 3D color Doppler may be partic-
ularly useful to image the entire THV border (Online
Video 14).
TRICUSPID BIOPROSTHETIC VIV. Biological tricuspid
valve replacements may also fail, requiring reinter-
ventions (59). Numerous investigators have reported
FIGURE 16 Inaccur
Incorrect positioning
plane imaging. In th
would perforate the
(Online Video 11). LV
FIGURE 15 Locating the Apical Cannulation Site
The ideal position for left ventricular transapical puncture can be guided by echocardiography. In these simultaneous multiplane images, the surgeon
pushes on the ventricle at the site of intended puncture (yellow arrow) from either the mid-esophageal views (A, Online Video 9) or transgastric views
(B, Online Video 10).
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974the successful implantation of a ﬁrst generation
balloon expandable valve or transcatheter pulmonary
valve into this position (60–63). Multiple venous ac-
cess routes have been used, including transjugular,
transatrial, and transfemoral. Valve sizing may be
assessed using echocardiography or computedate Positioning for Transapical LV Access
of the cannulation site is easily detected using simultaneous multi-
is example, the surgeon’s proposed cannulation site (yellow arrows)
right ventricle and likely cross the interventricular septum
¼ left ventricular.tomography. A major limitation is that the tricuspid
bioprosthesis is usually of a large diameter, requiring
larger THV sizes (64). If a transcatheter pulmonary
device is used, overexpansion of the device may
result in poor leaﬂet coaptation and reduced valve
durability (65). Pre-procedural imaging should
include measurement of the true ID of the surgical
valve and assessment of the angulation of the valveFIGURE 17 Position of First Generation Balloon Expandable
Valve in a Mitral VIV
The atrial edge of the ﬁrst generation balloon expandable valve
THV (yellow arrow) should be approximately 5 mm above the
imaged sewing ring (red arrow). See Online Video 12 for valve
deployment and Online Videos 13 and 14 for post-deployment
imaging. Abbreviations as in Figure 4.
FIGURE 18 Flared or Conical Deployment
Undersizing of the transcatheter valve for mitral VIV resulting in a nonﬂared contour (A, red rectangle) is a higher risk for valve embolization.
Adequate oversizing (typically >10%) should result in a ﬂared or conical shape to the THV (B, orange shape, and C, ﬂuoroscopy).
See also Figure 4A. Adapted from Bapat et al. (23). Abbreviations as in Figure 4.
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975relative to various access routes. Not infrequently,
the stability of the stiff wire (and thus the accurate
positioning of the THV) may be determined by this
angle. Coaxial positioning of the transcatheter valve
may not always be possible because of the access
angle (Figure 19, Online Video 15). Although standard
tricuspid valve imaging views should be attempted
(32), off-axis imaging is frequently required.
Pacing is frequently not performed for tricuspid
VIV, but if deemed necessary and in the absence of
a previous pacemaker, a temporary pacing wire for
tricuspid VIV may be positioned either in the coro-
nary sinus or the left ventricle. EchocardiographicFIGURE 19 Positioning of the Tricuspid VIV
Fluoroscopic imaging (A) and 3D imaging (B) are used to position a 29-
#33 mm tricuspid bioprosthetic valve (Perimount Pericardial valve, Edw
(yellow arrow) is 5 to 6 mm above the sewing ring (red arrows) just befoimaging may be helpful for positioning the pacing
wire using multiple views of the coronary sinus
(Figure 20). Tricuspid VIV has been performed in the
setting of pre-existing pacemaker wires with no
complications. The usual post-implant assessment
should be performed.
PULMONIC BIOPROSTHETIC VIV. The VIV procedure
in the pulmonic position has been successfully per-
formed using the transcatheter pulmonary valve (66),
as well as the second generation balloon expandable
valve (67). The majority of these patients have
congenital heart disease and a long history of
repeated surgical interventions, and thus the VIVmm second generation balloon expandable valve across a stenotic
ards Lifesciences, Irvine, California). The atrial edge of the THV
re deployment (Online Video 15). Abbreviations as in Figures 2 and 4.
FIGURE 20 Positioning of the Pacing Wire for Tricuspid VIV When a Previous Pacemaker Is Not Available
TEE can be used to help guide the pacing wire (yellow arrows) into the coronary sinus (blue arrow) by imaging either from the mid-esophageal view (A) or the
gastroesophageal junction view (B). Abbreviations as in Figures 2 and 4.
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976procedure, which has proven sustained beneﬁt, is an
attractive solution to pulmonic SHV failure. The pul-
monary valve is similar to the tricuspid valve in the
sense that it is a low-ﬂow valve and has a large EOA.
The second generation balloon expandable valve is
shorter than the transcatheter pulmonary valve and is
available in larger sizes.
Access for the pulmonary VIV procedure can be
through the femoral vein or internal jugular veinwith a
stiff guidewire placed into the pulmonary artery for
support. The pulmonic valve can usually be visualizedFIGURE 21 Pulmonic Bioprosthetic Valve Imaging
The pulmonic prosthesis or conduit can typically be imaged with slight
outﬂow (RVOT) view (A, red arrow). Panel B shows the color Doppler o
Online Video 16).from the mid-esophageal right ventricular outﬂow
view (Figure 21, Online Video 16) or transgastric right
ventricular inﬂow–outﬂow view (32). Although
extremely rare in the setting of bioprosthetic pulmonic
valve, the circumﬂex artery may theoretically become
obstructed with pulmonic VIV implantation, and a
diagnostic left coronary angiography during balloon
inﬂation may be the considered to exclude the risk of
coronary occlusion during implantation (68). Pacing is
not frequently performed for pulmonic VIV. The usual
post-implant assessment should be performed.manipulation of the probe from the mid-esophageal right ventricular
f severe bioprosthetic pulmonic regurgitation (yellow arrow,
FIGURE 22 Mitral Valve-in-Ring Procedure
In this example of an incomplete, rigid mitral annular ring (Edwards Classic) (A) placed in a patient with rheumatic changes, severe mitral stenosis developed (B) with
peak and mean gradients of 15 and 7 mm Hg with a calculated mitral valve area of 0.8 cm2. Multiplanar reconstruction of the 3-dimensional volume (C) shows the
dimensions of the rigid ring of 1.7  2.9 cm (annular area ¼ 409 mm2).
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977VALVE IN MITRAL OR TRICUSPID RING. Transcatheter
VIV implantation within a mitral or tricuspid annu-
loplasty ring is technically challenging. de Weger
et al. (69) were the ﬁrst to describe implantation of
a second generation balloon expandable valve in a
patient with a failed surgical mitral annuloplasty
ring. Unlike in a bioprosthesis, where the sewing
ring is nearly circular with little resulting inter-
valvular regurgitation post-VIV, mitral rings vary in
their rigidity, shape, and circumferential extent.
Valve-in-ring implantation into D-shaped rings,
particularly if the rings are rigid, may result inFIGURE 23 Position and Function of Valve-in-Ring
The ﬁnal position of the valve-in-ring (A, yellow arrows) should be at l
For the incomplete, rigid ring (Edwards Classic), there is a high likelihoo
of the ring (B, Online Video 17). In this instance, the peak and mean gra
THV ¼ transcatheter heart valve.paravalvular regurgitation as well as deformity of the
THV. LV outﬂow tract obstruction during deploy-
ment of the valve and rotation of the valve because
of the asymmetry of the ring is also possible. The
majority of valve-in-ring procedures have been per-
formed in complete rings; theoretically, an incomplete
ring may not give the THV enough stability. Two-
dimensional and 3D echocardiography can conﬁrm
the internal dimensions of the ring (Figure 22)
and exclude ring dehiscence, which may not beneﬁt
from the procedure. Access can be transapical or
transseptal (70).east 15% atrial to the ring (red arrows). This may reduce embolization into the ventricle.
d of intervalvular regurgitation, as well as deformity of the THV, because of the ﬁxed shape
dients (C) were mildly increased, with a calculated effective oriﬁce area of 1.3 cm2.
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978The THV should be positioned at least 15% atrial to
the annuloplasty ring (Figure 23A) to eliminate the
risk of leaﬂet ﬂaring and lessen the risk of LV outﬂow
tract obstruction or embolization into the ventricle.
Positioning the valve to atrial, however, risks para-
valvular regurgitation and migration into the atrium.
Post-deployment assessment (Figures 23B and 23C,
Online Video 17) is similar to other VIV procedures.
CONCLUSIONS
With an aging population and an increased frequency
of surgical bioprosthetic heart valve implantation,there will be a parallel increase in the need for repeat
valve replacement for bioprosthetic failure. The VIV
procedure is a viable alternative with acceptable
outcomes. Echocardiography is an integral part of the
pre-procedural assessment of the SHV and can be
used as an adjunct to ﬂuoroscopic imaging during and
immediately following VIV implantation.
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